AU2017205343A1 - Self-crosslinking antibodies - Google Patents

Self-crosslinking antibodies Download PDF

Info

Publication number
AU2017205343A1
AU2017205343A1 AU2017205343A AU2017205343A AU2017205343A1 AU 2017205343 A1 AU2017205343 A1 AU 2017205343A1 AU 2017205343 A AU2017205343 A AU 2017205343A AU 2017205343 A AU2017205343 A AU 2017205343A AU 2017205343 A1 AU2017205343 A1 AU 2017205343A1
Authority
AU
Australia
Prior art keywords
ser
leu
gly
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017205343A
Other languages
English (en)
Inventor
Calin DUMITRU
Elisabeth M. Gardiner
Michael H. MATHO
Robert P. Mckenzie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meditope Biosciences Inc
Original Assignee
Meditope Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meditope Biosciences Inc filed Critical Meditope Biosciences Inc
Publication of AU2017205343A1 publication Critical patent/AU2017205343A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017205343A 2016-01-08 2017-01-09 Self-crosslinking antibodies Abandoned AU2017205343A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662276803P 2016-01-08 2016-01-08
US62/276,803 2016-01-08
US201662317342P 2016-04-01 2016-04-01
US62/317,342 2016-04-01
PCT/US2017/012754 WO2017120599A1 (en) 2016-01-08 2017-01-09 Self-crosslinking antibodies

Publications (1)

Publication Number Publication Date
AU2017205343A1 true AU2017205343A1 (en) 2018-07-19

Family

ID=59274084

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017205343A Abandoned AU2017205343A1 (en) 2016-01-08 2017-01-09 Self-crosslinking antibodies

Country Status (8)

Country Link
US (1) US11459397B2 (enExample)
EP (1) EP3399992A4 (enExample)
JP (1) JP6983808B2 (enExample)
KR (1) KR20180098672A (enExample)
CN (1) CN108712908A (enExample)
AU (1) AU2017205343A1 (enExample)
CA (1) CA3010632A1 (enExample)
WO (1) WO2017120599A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017215350A1 (en) * 2016-02-02 2018-08-09 Meditope Biosciences, Inc. Anti-EGFR antibody drug conjugate
EP3765523A1 (en) * 2018-03-12 2021-01-20 Memorial Sloan Kettering Cancer Center Bispecific binding agents and uses thereof
CN109521192B (zh) * 2018-11-27 2021-07-13 柏荣诊断产品(上海)有限公司 一种提高胶乳比浊试剂检测灵敏度的方法
KR20220078665A (ko) * 2019-10-10 2022-06-10 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 다중특이적 면역 세포 인게이저를 발현하는 종양용해 바이러스
EP4025250A4 (en) * 2019-10-12 2024-01-17 Bio-Thera Solutions, Ltd. FORMULATION OF ANTI-CD20 ANTIBODIES AND USE OF ANTI-CD20 ANTIBODIES FOR THE TREATMENT OF CD20-POSITIVE DISEASES
JPWO2021112249A1 (enExample) * 2019-12-06 2021-06-10
MX2022011701A (es) * 2020-03-23 2022-10-07 Bristol Myers Squibb Co Anticuerpos anti-receptor de quimiocina 8 con motivo c-c (ccr8) para el tratamiento del cancer.
WO2022068141A1 (zh) * 2020-09-29 2022-04-07 昆明赛诺制药股份有限公司 人源化抗-cd22重组免疫毒素及其应用
CN112661828B (zh) * 2021-01-15 2022-04-01 武汉大学 一种突触素的抗原肽及其抗体与应用
WO2022158554A1 (ja) * 2021-01-22 2022-07-28 味の素株式会社 二量体化した環状ペプチドをスクリーニングする方法
CA3212386A1 (en) * 2021-03-18 2022-09-22 Alessandro ARCOVITO Ferritin variants with increased stability and complexation ability
CN115677856B (zh) * 2021-07-29 2023-11-28 东莞市朋志生物科技有限公司 抗人IgM抗体及其应用
JP2024025400A (ja) * 2022-08-12 2024-02-26 浜松ホトニクス株式会社 膜貫通タンパク質を標的オルガネラに局在化させるためのペプチドリンカー及び局在化方法並びに局在化する融合タンパク質

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1293514B1 (en) * 2001-09-14 2006-11-29 Affimed Therapeutics AG Multimeric single chain tandem Fv-antibodies
AU2005266184A1 (en) * 2004-07-26 2006-02-02 Asterion Limited Linkers
US20140127200A1 (en) * 2008-01-03 2014-05-08 The Scripps Research Institute Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains
US8962804B2 (en) * 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
SG189313A1 (en) * 2010-10-08 2013-05-31 John C Williams A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
CN114634572A (zh) * 2011-10-10 2022-06-17 希望之城公司 中间位和中间位结合抗体及其用途
US9428553B2 (en) * 2012-02-10 2016-08-30 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
CN117442748A (zh) * 2014-10-02 2024-01-26 希望之城公司 多价中间表位、中间表位结合抗体及其用途
ES2852973T3 (es) * 2015-05-15 2021-09-14 Hope City Composiciones de receptores de antígeno quimérico
AU2017215350A1 (en) * 2016-02-02 2018-08-09 Meditope Biosciences, Inc. Anti-EGFR antibody drug conjugate

Also Published As

Publication number Publication date
JP6983808B2 (ja) 2021-12-17
KR20180098672A (ko) 2018-09-04
US11459397B2 (en) 2022-10-04
WO2017120599A1 (en) 2017-07-13
JP2019509054A (ja) 2019-04-04
EP3399992A4 (en) 2019-07-31
US20190016822A1 (en) 2019-01-17
CA3010632A1 (en) 2017-07-13
CN108712908A (zh) 2018-10-26
EP3399992A1 (en) 2018-11-14

Similar Documents

Publication Publication Date Title
AU2020289727B2 (en) Multivalent meditopes, meditope-binding antibodies and uses thereof
US11459397B2 (en) Self-crosslinking antibodies
JP7051692B2 (ja) Pd-1に特異的に結合する抗体及びその使用
CN118667012A (zh) Fcrn抗体及其使用方法
KR20230137393A (ko) Psma 결합 단백질 및 이의 용도
CN116096753A (zh) 对abcb5具有特异性的抗体及其用途
TW202540203A (zh) 結合pdgf-b與pdgf-d的抗原結合分子及使用方法
HK1242589A1 (en) Multivalent meditopes, meditope-binding antibodies and uses thereof
HK1242589B (en) Multivalent meditopes, meditope-binding antibodies and uses thereof

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application